Quantum-Si Incorporated is a life sciences company focused on proteomics research, providing single-molecule protein sequencing (NGPS) technology. The company develops proprietary instrumentation, software, and consumables to enable massively parallel protein sequencing, offering an alternative to legacy methods like mass spectrometry and Edman degradation. Its current product line includes the Platinum NGPS instruments, Platinum Pro benchtop sequencer, Platinum Analysis Software, and associated consumable kits. The company is developing Proteus, a next-generation modular platform anticipated for launch by the end of 2026, which provides higher sequencing output and automated workflows. Quantum-Si serves academic centers, industry partners, and research laboratories globally, supporting applications in biomarker discovery, drug development, disease detection, and systems biology. Founded in 2013 by Jonathan Rothberg, the company completed a business combination in 2021 to become a public entity. The technology utilizes single-molecule kinetic detection to analyze post-translational modifications, protein variants, and proteoforms with high resolution.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage quantum-si.com
Sector Healthcare IR page quantum-si.com
Tags
proteomics, protein sequencing, single-molecule detection, biomarker discovery, drug development, post-translational modifications, life sciences, research instrumentation, Platinum, Platinum Pro, Proteus, Platinum Analysis Software, Q-SI Operations Inc., HighCape Capital Acquisition Corp.
Press page quantum-si.com/news-events/press-releases

Metrics

Valuation  
Market cap $ 234.313M
Market cap (USD) $ 234.313M
P/E -2.82
PEG —
P/BV 1.46
P/S 185.23
P/OCF -2.90
P/FCF -2.88
Dividend yield —
Turnover / mcap —
Returns  
ROE -46.5%
ROI -50.4%
ROIC -43.3%
Profit margin -4,160.1%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 36
Quality score -73.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 2.436M 3.058M 1.082M — — —
Net profit -101.339M -101.007M -95.96M -132.442M -94.989M -36.613M
Free cash flow -97.234M -92.378M -98.546M -101.301M -72.576M -33.034M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 1.1 2.7 2.01 1.83 7.87 —
Price performance 12m -0.59 0.34 0.1 -0.77 — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — 0.00 368,000 1.33M 561,000
↳ YoY growth +262.2% -57.9%
Lease liabilities (USD) — — 0.00 8.08M 17.4M 15.3M 12.9M 4.17M
Cash and deposits (USD) 46.7M 32.9M 1.03M 35.8M 84.3M 134M 49.2M 21.6M
Intangible assets (USD) — — — — 0.00 532,000 0.00 —
Right-of-use assets (USD) — — 0.00 6.97M 15.8M 14.4M 13.1M 3.46M
Cash flow detail
Operating cash flow (USD) — -30.7M -32.6M -66.8M -90.6M -94M -87.8M -94.7M
Purchases of property, plant and equipment (USD) — -1.24M -461,000 -5.76M -10.7M -4.51M -4.58M -2.52M
Change in receivables (cash effect) (USD) — — — 0.00 0.00 -368,000 -1.09M 626,000
Change in inventories (cash effect) (USD) — — — 0.00 0.00 -3.1M 4.34M -2.01M
Change in payables (cash effect) (USD) — -270,000 536,000 709,000 721,000 -1.22M 390,000 -338,000
Income taxes paid (cash effect) (USD) — — — — — 0.00 0.00 -24,000
Share-based compensation (USD) — 2.72M 1.92M 24.9M 11.2M 8.52M 8.89M 10.8M
Operating cash flow before change in receivables (USD) — — — -66.8M -90.6M -93.7M -86.7M -95.3M
Free cash flow (OCF - PPE - intangibles) (USD) — -31.9M -33M -72.6M -101M -98.5M -92.4M -97.2M
Income detail
Research and development expense (USD) — 28.1M 27.6M 46.6M 72.1M 67M 59.6M 53.8M
↳ 5y CAGR +16.2% +14.3%
Total comprehensive income (USD) — -35.8M -36.6M -95M -132M -96M -101M -101M
Comprehensive income to owners (USD) — -35.8M -36.6M -95M -132M -96M -101M -101M
Provision for credit losses (USD) — — — — 0.00 0.00 124,000 146,000
Credit cost ratio (credit losses / average receivables) (%) — — — — — 0.0% 14.6% 15.4%
Reported Mar 1, 2022 Mar 1, 2022 Mar 1, 2022 Feb 29, 2024 Mar 3, 2025 Mar 3, 2026 Mar 3, 2026 Mar 3, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Quantum-Si Incorporated — Regulation FD Disclosure Bull 3 Bear 0 Product/operations

From time to time, Quantum-Si Incorporated (the “Company”) distributes press releases to the investment community to provide updates and summaries of its business. On November 18, 2026, the Company issued a press release announcing that it has demonstrated detection of all 20 naturally occurring amino acids in its Proteus™ development program. This press release is also furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The furnishing of the information in this Item 7.01 and Exhibit 99.1 is not intended to, and does not, constitute a determination or admission by the Company that the information in this report is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company or any of its affiliates.

Forward-looking Statements

Certain information discussed in this Current Report on Form 8-K is forward-looking information that involves risks, uncertainties and assumptions. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “condition,” “expect,” “if,” “intend,” “may,” “will,” “planned” and similar expressions.

BRANFORD, Conn., November 5, 2026 (GLOBE NEWSWIRE) — Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule protein sequencing, today announced financial results for the third quarter ended September 30, 2026.

Press Release Highlights

•Reported third quarter 2026 revenue of $212,000 during the transition period from Platinum® to Proteus, which is expected to continue through the first half of 2027

•Highlighted interim Proteus performance data presented at World HUPO including approximately 30 times more sequencing output per chamber in a controlled peptide study

•Highlighted detection of 19 amino acids, with the 20th expected before year-end

•Announced launch of the Proteus pre-order program

•Updated full-year 2026 guidance for lower adjusted total operating expenses and lower total cash usage, and reaffirmed cash runway into the fourth quarter of 2028

“We made significant progress during the third quarter as we continued to advance Proteus toward commercial launch,” said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si.

October 16, 2026

BRANFORD, Conn., Oct. 16, 2026 (GLOBE NEWSWIRE) — Quantum-Si Incorporated (opens in a new window) (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will provide a business update and report financial results for the third quarter 2026 on Thursday, November 5, 2026. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call on the same day at 4:30 PM ET.

Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations (opens in a new window) .

Alternatively, individuals can register here (opens in a new window) to receive a dial-in number and personalized PIN to participate in the call. An archived webcast of the event will be available for replay following the event.

**About Quantum-**Si Incorporated
Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company’s platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at quantum-si.com (opens in a new window)  or follow us on LinkedIn (opens in a new window)  or X (opens in a new window) .

Investor & Media Contact
Jeff Keyes
Chief Financial Officer
[email protected] (opens in a new window)

Source: Quantum-Si Incorporated


Primary Logo

RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.

Quantum-Si

Contact Us

© Copyright 2026 Quantum-Si Incorporated. All rights reserved

Terms and Conditions   |  Privacy Policy   |  Patents   |  Legal Disclaimer

Back to top

Prompts

Quantum-Si Incorporated (ticker QSI), listed in United States.

Company History

Date Change Detail
Mar 26, 2021 Renamed HIGHCAPE CAPITAL ACQUISITION CORP. → QUANTUM-SI INC
— Former tickers CAPA, QSIAW

ETFs Holding Quantum-Si Incorporated

ETF Weight in ETF Shares Market value As of
ARKG 0.42% 7,523,110 $ 7.598M Nov 18, 2026